Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease

Hepatology

Volumn 61, Issue 6, 2015, Pages 1860-1869

  Leidner, Andrew J ^a   Chesson, Harrell W ^a   Xu, Fujie ^a   Ward, John W ^a   Spradling, Philip R ^a   Holmberg, Scott D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CHRONIC LIVER DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; GENOTYPE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; THERAPY DELAY; VIRUS TRANSMISSION; COST BENEFIT ANALYSIS; ECONOMICS; STATISTICAL MODEL;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEPATITIS C; HUMANS; MODELS, ECONOMIC;

EID: 84929582795     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27736     Document Type: Article

References (46)

1. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156:271-278.
2. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med 2012;156:263-270.
3. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2000;133:665-675.
4. Xu F, Tong X, Leidner AJ. Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase. Health Affairs 2014;33:1728-1735.
5. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013;368:1859-1861.
6. Volk ML, Tocco R, Saini S, Lok ASF. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009;50:1750-1755.
7. Spradling PR, Rupp L, Moorman AC, Lu M, Teshale EH, Gordon SC, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis 2012;55:1047-1055.
8. Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010;30:240-250.
9. American Association for the Study of Liver Diseases/Infectious Diseases Society of America/International Antiviral Society-USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed August 15, 2014.
10. Moorman AC, Gordon SC, Rupp LB, Spradling PR, Teshale EH, Lu M, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study. Clin Infect Dis 2013;56:40-50.
11. Holmberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, et al. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus: patients in a large US cohort. Clin Infect Dis 2013;57:240-246.
12. Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Appl Health Econ Health Policy 2013;11:65-78.
13. Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 2011;14:1068-1077.
14. Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepatitis 2013;20:847-857.
15. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis CA cost-effectiveness analysis. Ann Intern Med 2012;156:279-290.
16. Yi Q, Wang P, Krahn M. Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection. J Viral Hepatitis 2004;11:166-174.
17. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-431.
18. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-337.
19. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufor JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis: sustained virological response and all-cause mortality. JAMA 2012;308:2584-2593.
20. Pollack A. F.D.A. approves pill to treat hepatitis C. New York Times, December 6, 2013.
21. Lawitz E, Poordad F, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-523.
22. Lawitz E, Vierling JM, Murillo A, Kugelmas M, Gerstoff J, Balart LA, et al. High efficacy and saftety of the all-oral combination regimen, Mk-5172/MK-8742 +/- RBV for 12 weeks in HCV genotype 1 infected patients: the C-Worthy study. Presented at: The Liver Meeting: The 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 3, 2013; Washington DC.
23. Lawitz E, Hezode C, Varunok P, Thuluvath J, Baykal T, Kapoor M, et al. Interferon- and ribavirin-free regimen of ABT-450/r+ABT-267 in HCV genotype 1b-infected treatment-naive patients and prior null responders. Presented at: The Liver Meeting: The 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 3, 2013; Washington DC.
24. Jacobson IM, Ghalib RH, Rodriguez-Torres M, Younossi ZM, Corregidor A, Sulkowski MS, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Presented at: The Liver Meeting: The 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 3, 2013; Washington DC.
25. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
26. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C. JAMA 1998;280:2088-2093.
27. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-865.
28. Carithers RL Jr, Sugano D, Bayliss M. Health assessment for chronic HCV infection. Dig Dis Sci 1996;41:75S-80S.
29. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002;35:704-708.
30. Foster G, Goldin R, Thomas H. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-212.
31. Schwarzinger M, Dewedar S, Rekacewicz C, Abd Elaziz KM, Fontanet A, Carrat F, et al. Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural Egypt. Hepatology 2004;40:1434-1441.
32. Castera L, Constant A, Bernard P-H, de Ledinghen V, Couzigou P. Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases. World J Gastroenterol 2006;12:1545.
33. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999;30:1299-1301.
34. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005;41:790-800.
35. Younossi ZM, Mendel ES, Heshaam MM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014;60:530-537.
36. Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, et al. Should we await INF-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis. J Hepatol 2014;61:7-14.
37. Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, et al. Cost-effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the Veterans Health Administration. Clin Gastroenterol Hepatol 2013;11:1503-1510.
38. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012;54:1259-1271.
39. McEwan P, Ward T, Yuan Y, Kim R, L'Italien G. The impact of timing and prioritization on the cost-effectiveness of birth-cohort testing and treatment for hepatitis C virus in the US. Hepatology 2013;58:54-64.
40. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012;55:1344-1355.
41. Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE. Cost-effectiveness of screening for chronic hepatitis C infection in the US. Clin Infect Dis 2013;56:1382-1393.
42. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293-301.
43. Mahajan R, Xing J, Liu SJ, Ly KN, Moorman AC, Rupp L, et al. Mortality among persons in care with hepatitis C virus infection-the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis 2014;58:1055-1061.
44. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013;58:1598-1609.
45. Razavi H, El Khoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013;57:2164-2170.
46. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.